Invivyd Inc.
$ 1.61
-6.40%
14 Apr - close price
- Market Cap 486,063,000 USD
- Current Price $ 1.61
- High / Low $ 1.78 / 1.58
- Stock P/E N/A
- Book Value 0.86
- EPS -0.30
- Next Earning Report 2026-05-21
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.17 %
- ROE -0.34 %
- 52 Week High 3.07
- 52 Week Low 0.46
About
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases in the United States. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$10.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-26 | 2025-11-06 | 2025-08-15 | 2025-05-07 | 2025-03-26 | 2024-11-07 | 2024-08-14 | 2024-05-09 | 2024-03-28 | 2023-11-09 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.0393 | -0.06 | -0.12 | -0.14 | -0.15 | -0.51 | -0.4 | -0.38 | -0.67 | -0.36 | -0.46 | -0.32 |
| Estimated EPS | -0.0864 | -0.07 | -0.02 | -0.01 | -0.1 | -0.35 | -0.37 | -0.47 | -0.42 | -0.5 | -0.34 | -0.3 |
| Surprise | 0.0471 | 0.01 | -0.1 | -0.13 | -0.05 | -0.16 | -0.03 | 0.09 | -0.25 | 0.14 | -0.12 | -0.02 |
| Surprise Percentage | 54.5139% | 14.2857% | -500% | -1300% | -50% | -45.7143% | -8.1081% | 19.1489% | -59.5238% | 28% | -35.2941% | -6.6667% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-21 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.08 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IVVD
2026-04-12 20:38:52
Invivyd's stock rose after the company provided an update from its late-stage trial for its experimental COVID-19 antibody therapy, VYD222. The therapy demonstrated potent neutralizing activity against various SARS-CoV-2 variants, including JN.1, suggesting its potential effectiveness. The positive results indicate progress for Invivyd in developing a treatment for the evolving COVID-19 landscape.
2026-04-10 02:10:38
Invivyd's stock rose after the company provided an update on its late-stage trial for a COVID-19 therapy. The news suggests positive developments for the investigational treatment.
2026-04-10 02:09:44
The article states that Invivyd's stock rose following a positive update from a late-stage trial for its COVID-19 therapy. However, the provided content is empty and does not contain the details of this update or the trial.
2026-04-10 00:09:43
Invivyd, Inc. (IVVD) has released a slide deck discussing the progress of its REVOLUTION Clinical Program. The company also highlighted the advancement of its measles monoclonal antibody candidate. This information is presented in a slideshow format for investors.
2026-04-09 19:09:43
Invivyd announced its plans to develop VMS063, an antibody drug targeting measles, intended as a treatment or preventive option for those who cannot or will not receive the vaccine. This comes as measles cases in the U.S. have reached a decades-high level due to declining vaccination rates. The company hopes to advance VMS063 to human testing by late 2026, while also providing an update on its lead COVID-19 antibody program.
2026-04-09 17:42:00
Invivyd, Inc. discussed the progress of its REVOLUTION Clinical Program and the advancement of its measles monoclonal antibody candidate. This information was presented in a slide deck published by the company. The article was written by SA Transcripts, which focuses on developing and publishing earnings call transcripts.
